LifeView, a brand of Genomic Prediction, provides genetic testing and screening for embryos created through in vitro fertilization (IVF). Its services are designed to help patients and their fertility care teams make informed decisions about embryo selection, with the aim of reducing miscarriage risk and genetic disease and improving treatment outcomes.

LifeView offers several preimplantation genetic testing options. PGT-A screens for chromosome number abnormalities, while PGT-A+ can help identify whether an abnormality originated from the egg or sperm. PGT-M is intended for inherited single-gene conditions, and PGT-SR helps identify embryos affected by chromosome rearrangements. The company also offers M2 testing, which screens biological parents for a haplotype associated with increased miscarriage risk.

The Embryo Health Score test, also called PGT-P, assesses genetic variants linked to polygenic conditions, including diabetes, cancer, schizophrenia, and heart disease, helping patients and clinicians compare risk estimates among embryos. LifeView provides access to in-house genetic counselors and works with fertility benefit and financing providers.